All terms in NCIT
| Label | Id | Description |
|---|---|---|
| Widely Invasive Lesion | NCIT_C60987 | |
| Ring Dosage Form | NCIT_C60988 | [A solid composed active and/or inert ingredient(s) of in the shape of a hoop.] |
| Stethescope | NCIT_C69320 | [A medical instrument for listening to the sounds generated inside the body.] |
| ADCS-ADL Severe Dementia - Description of Optimal Performance of Walking | NCIT_C106980 | [Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, Severe Dementia (ADCS-ADL Severe Dementia) Regarding walking (or getting around in a wheelchair) in the past 4 weeks, which best describes subject's optimal performance?] |
| ADCS-ADL Severe Dementia - Usual Bowel and Bladder Function at Toilet | NCIT_C106981 | [Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, Severe Dementia (ADCS-ADL Severe Dementia) Regarding bowel and bladder function at the toilet, which best describes subject's usual performance during the past 4 weeks?] |
| ADCS-ADL MCI - Subscore for Items 4 to 7 | NCIT_C106971 | [Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) Subscore for page 2. (Range = 0-8).] |
| Drop Solution Dosage Form | NCIT_C60992 | [A solution intended for administration in a drop-wise fashion.] |
| ADCS-ADL MCI - Subscore for Items 8 to 10 | NCIT_C106972 | [Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) Subscore for page 3. (Range = 0-10).] |
| Neoplastic Epithelial Small Polygonal Cell | NCIT_C60993 | |
| Neoplastic Epithelial Polygonal Cell | NCIT_C37036 | |
| ADCS-ADL MCI - Subscore for Items 11 to 12 | NCIT_C106973 | [Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) Subscore for page 4. (Range = 0-7).] |
| Gel Forming Drop Solution Dosage Form | NCIT_C60994 | [A solution intended for administration in a drop-wise fashion; it becomes gelatinous upon administration.] |
| ADCS-ADL MCI - Subscore for Items 13 to 14 | NCIT_C106974 | [Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) Subscore for page 5. (Range = 0-6).] |
| Drop Suspension Dosage Form | NCIT_C60995 | [A suspension intended for administration in a drop-wise fashion.] |
| Drop Dosage Form | NCIT_C29012 | [A substance intended for administration in a drop-wise fashion.] |
| ADCS-ADL MCI - Subscore for Items 15 to 16 | NCIT_C106975 | [Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) Subscore for page 6. (Range = 0-5).] |
| Liver X Receptor beta Agonist RGX-104 | NCIT_C131910 | [An orally bioavailable agonist of the nuclear receptor liver X receptor beta (LXRbeta; NR1H2; LXR-b), with potential immunomodulating and antineoplastic activities. Upon oral administration, LXRbeta agonist RGX-104 selectively targets and binds to LXRbeta, thereby activating LXRbeta-mediated signaling, leading to the transcription of certain tumor suppressor genes and the downregulation of certain tumor promoter genes. This particularly activates the expression of apolipoprotein E (ApoE), a tumor suppressor protein, in tumor cells and certain immune cells. This activates the innate immune system, resulting in depletion of immunosuppressive myeloid-derived suppressor cells (MDSCs), tumor cells and endothelial cells in the tumor microenvironment. This reverses immune evasion, enhances anti-tumor immune responses and inhibits proliferation of tumor cells. LXRbeta, a member of the oxysterol receptor family, which is in the nuclear receptor family of transcription factors, plays a key role in cholesterol transport, glucose metabolism and the modulation of inflammatory responses; activation of LXRbeta suppresses tumor cell invasion, angiogenesis, tumor progression, and metastasis in a variety of tumor cell types. The expression of the ApoE protein becomes silenced in human cancers as they grow, become invasive, and metastasize; ApoE silencing is related to reduced survival in cancer patients. The LXR-ApoE pathway regulates the ability of cancers to evade the immune system and recruit blood vessels.] |
| ADCS-ADL MCI - Subscore for Item 17 | NCIT_C106976 | [Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) Subscore for page 7. (Range = 0-4).] |
| Burkitt-Like Lymphoma with 11q Aberration | NCIT_C131911 | [A molecularly distinct B-cell lymphoma reminiscent of Burkitt lymphoma. It is characterized by the absence of MYC translocation and the presence of chromosome 11q aberrations.] |
| Aggressive Non-Hodgkin Lymphoma | NCIT_C9244 | [A non-Hodgkin lymphoma with an aggressive clinical course. Representative examples include Burkitt lymphoma, mantle cell lymphoma, and angioimmunoblastic T-cell lymphoma.] |